Please upgrade your browser.
AVEO is initially receiving $15 million. Under the terms of the license agreement, AVEO will receive the first half of this amount as an up-front payment from Centocor Ortho Biotech.
Pfizer says it asked European Union to approve its kidney cancer drug candidate axitinib
Oregon Health & Science University Knight Cancer Institute researchers uncovered a gene that may be the key to helping kidney cancer patients who don't respond to current therapies.
AVEO supports KCA
Mediaplanet Publishing released a Kidney Health report to targeted markets in USA Today. The report is distributed to 1 million readers with contributions from Kidney Cancer Association, National Kidney Foundation, Fresenius Medical Care North America, UKidney, Medical Education Institute, and National Kidney Registry.
Active surveillance may be a viable short-term treatment option in select patients with small renal masses, researchers from Fox Chase Cancer Center, Philadelphia.
Learn about state-of-the art treatment of kidney cancer from world-renown experts.
Independent Sector urges Congress to reject proposals to limit the value of itemized deductions for charitable donations. As nonprofit organizations struggle to meet increased demand for services and raise the necessary funds to meet those needs, Congress should seek to encourage all individuals, regardless of income and wealth, to give more to charitable organizations.
High Cost-Sharing and Higher Concurrent Prescription Activity Are Key Factors Related to Abandonment of Medicines
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX - News) today announced that data evaluating the use of Nexavar® (sorafenib) tablets will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago.
|Powered by NeonCRM|